ArticleMolecules (Basel, Switzerland)2024
Effects of Metamizole, 4-Methylaminoantipyrine, and 4-Aminoantipyrine on LX-2 Liver Cell Line Viability and Apoptosis.
Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metamizole (dipyrone) is a non-opioid analgesic widely used in human and veterinary medicine, despite ongoing concerns about its safety due to risks such as agranulocytosis and potential hepatotoxicity. This study investigates the cytotoxic (MTT assay) and pro-apoptotic effects of metamizole and its primary metabolites, 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA), on the LX-2 liver cell line. These metabolites are implicated in both the therapeutic and adverse effects of the drug. The objective is to elucidate the mechanisms of potential hepatotoxicity, with a focus on cell viability and apoptosis. Metamizole was tested at five concentrations (100, 200, 400, 600, and 1000 µg/mL), while its metabolites were tested at two concentrations (100 and 1000 µg/mL). The results show a dose-dependent decrease in cell viability, with significant reductions at higher concentrations. The greatest cytotoxic effects were observed with 4-AA and 4-MAA, which induced marked apoptosis at 1000 µg/mL. This study concludes that metamizole and its metabolites can cause liver cell damage, underscoring the importance of caution in its clinical use and the need for further research to ensure its safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.